In mature organisms, quiescent cells typically exhibit heightened replication rates during tumorigenesis or as part of the tissue repair process following injury [27]. Within the renal glomerulus, various forms of injury can incite localized inflammatory reactions involving resident glomerular cells. These injuries may arise from immune-mediated responses, infections, toxins, mechanical stress, or other causative factors [28]. A prominent histopathological feature of numerous human and experimental glomerular inflammatory conditions is an increase in cellular density within the mesangium. This increase is attributed to the proliferation of mesangial cells (MCs) and the influx of leukocytes [29]. Irrespective of the specific injury mechanism, an early and pivotal factor in the development of progressive glomerular injury and glomerulosclerosis seems to be an imbalance in regulating MC proliferation. In experimental models of nephritis, MC proliferation frequently precedes and correlates with an increase in the accumulation of extracellular matrix (ECM) within the mesangium and the subsequent development of glomerulosclerosis [30–31]. Moreover, interventions that reduce cell proliferation in glomerular disease models, such as treatment with heparin, a low-protein diet, or the use of neutralizing antibodies against platelet-derived growth factor, have been demonstrated to mitigate ECM expansion and sclerotic changes[32]. Notably, a reduction in MC replication is correlated with a marked decrease in mesangial ECM accumulation and diminished deposition of collagen type IV, laminin, and fibronectin [33]. However, the specific molecular mechanisms underlying the abnormal proliferation of mesangial cells in various types of nephritis, including IgA nephropathy, have yet to be fully elucidated.
In the 1920s, Otto Warburg and his colleagues made an important observation that tumors exhibit an unusually high rate of glucose uptake in comparison to the surrounding tissue. Furthermore, they noted that glucose was metabolized to produce lactate even when oxygen was present, which led to the coining of the term "aerobic glycolysis."[34]. The Warburg effect has been postulated to be an adaptive mechanism aimed at fulfilling the biosynthetic demands associated with uncontrolled cell proliferation. In this context, increased glucose consumption serves as a carbon source for the anabolic processes required to facilitate cell proliferation. Excess carbon is allocated for the synthesis of new nucleotides, lipids, and proteins and can be channeled into various branching pathways that stem from glycolysis[35–36]. Furthermore, the Warburg effect may offer a growth advantage to cells within a multicellular environment[37]. However, the reason behind this relatively inefficient metabolic pathway in tumor cells remains unclear. However, current research points to mitochondrial dysfunction in cancer cells and changes in essential enzymes such as pyruvate kinase (PK), which are involved in glycolysis[38]. PK plays a crucial role in glycolysis by catalyzing the final and physiologically irreversible step, which involves converting phosphoenolpyruvate into pyruvate through the transfer of a phosphate group to adenosine diphosphate [39]. In mammals, there are four distinct PK isoforms encoded by two genes. The PKLR gene encodes PKL and PKR. The PKM gene encodes PKM1 and PKM2 through alternative splicing, utilizing mutually exclusive exons that are the same length but encode a 56-amino acid region differing at 22 residues[40]. PKM2 is universally expressed during embryogenesis, regeneration, and cancer development. This observation implies that the capacity to regulate pyruvate kinase enzymatic activity is a crucial factor in actively proliferating cells[41]. Numerous studies have indicated that elevated levels of PKM2 in circulation could serve as a diagnostic marker for various cancer types. Furthermore, the overexpression of PKM2 is positively correlated with tumor progression, primarily owing to its involvement in glycolysis, proliferation, and apoptosis[42]. A reduction in PKM2 expression has been demonstrated to lower the glycolytic rate and inhibit tumor growth in various types of cancer. Administering the PKM2 activator TEPP-46 to H1299 xenograft model mice resulted in a delay in tumor onset and the development of smaller tumors compared to those in control mice that received a vehicle[43]. Similarly, the deletion of PKM2 in a xenograft mouse model of NCI-N87 cells led to the formation of smaller tumors than those formed in the control counterparts[44]. Intriguingly, an expanding body of literature offers substantiating evidence regarding the potential of PKM2 as a biomarker for nephrotoxicity. This growing interest in revealing the possible involvement of PKM2 in renal diseases is well founded. In a recent study, the induction of nephrotoxicity in rats through cisplatin led to a notable increase in urinary PKM2 levels, which coincided with elevated lactate excretion and significant alterations in amino acids, glucose, and TCA intermediates within the urine. Correspondingly, renal tubular HK-2 cells exposed to cisplatin, as well as other nephrotoxic agents such as cyclosporine A, exhibited increased PKM2 secretion in conditioned media[45]. Furthermore, Chen et al. reported that PKM2 contributes to kidney fibrosis, particularly during the transition from acute kidney injury to chronic kidney disease[46]. These collective findings underscore PKM2 as a substantial contributor to renal function and a potential novel marker for nephrotoxicity. These discoveries suggest that targeting PKM2 could represent an innovative strategy for the prevention and treatment of renal diseases. In our study, we noted a significant increase in lactate and PKM2 expression in the kidneys of IgA model mice. Silencing PKM2 resulted in pronounced inhibition of LPS-induced aerobic glycolysis and proliferation in human mesangial cells. Notably, the expression of PKM2 gradually diminishes during the transition from embryonic development to mature tissue. However, PKM2 expression resurfaces during tissue repair and tumor growth, implying that its regulation in tissue cells is strictly controlled by molecular regulation. Research has demonstrated that miRNAs can bind to PKM2 mRNA, effectively suppressing its expression during gene translation. This suppression can decelerate cellular glycolysis and hinder tumor growth. Hence, there is a growing focus on the regulation of PKM2 by noncoding genes.
Unlike the majority of linear messenger RNAs and long noncoding RNAs, which are characterized by 5′ N7-methylguanosine caps at the beginning and 3′ polyadenylated tails at the end, circular RNAs represent a distinct class of RNA molecules[47]. Circular RNAs are characterized by their unique feature of being covalently closed single-stranded RNAs. These circular RNAs have recently gained recognition as a prevalent category of RNA species[48]. The circular nature of single-stranded RNA was initially observed in plant viroids, and subsequently, circular transcripts were discovered in eukaryotes through electron microscopic evidence, revealing a circular morphology despite their unknown functions[49]. In the 1980s, other examples of circular RNA genomes were identified, as was the case for the hepatitis δ virus. Over the past decade, the emergence of RNA sequencing technologies, enriched for nonpolyadenylated and circular transcriptomes, along with computational tools for circular RNA annotation, has revealed the widespread expression of circRNAs across various metazoan cell types and tissues[50]." A groundbreaking discovery in 2013 highlighted the ability of circRNAs to act as "molecular sponges" that bind and inhibit corresponding miRNAs and consequently enhance the expression of the miRNA target genes[51]. Liao et al. reported that circRNA_45478, which functions as a miR-190a-5p sponge, exacerbates ischemic acute kidney injury[52]. Furthermore, circPlekha7 inhibits the epithelial-to-mesenchymal transition of renal tubular epithelial cells by targeting miR-493-3p to derepress KLF4 expression[53]. Recent comparisons of urinary circRNA profiles between IgAN patients and healthy controls highlighted the upregulation of circRNA_0013747 in IgAN patients, with an associated expression pattern with PKM2[54]. These findings suggested that circRNA_0013747 may play an important role in the onset and progression of IgA nephropathy. In our study, we demonstrated that circRNA_0013747 was significantly upregulated in the kidney tissue of IgA nephropathy patients and promoted mesangial cell proliferation through the induction of PKM2-mediated aerobic glycolysis. Our results confirm the central role of the circRNA_0013747/miR-330-3p/PKM2 axis in driving aerobic glycolysis and mesangial cell proliferation in IgAN. Nevertheless, our study has certain limitations. We did not investigate the relationship between circRNA_0013747 expression and clinicopathological parameters such as mesangial IgA deposition and renal interstitial lymphocyte infiltration. The exact distribution of circRNA_0013747 in the kidney has not been determined, and its specific impact on mesangial cells has yet to be determined. Finally, whether this molecular target can be applied in clinical diagnosis and treatment requires further investigation.
To summarize, our research provides a novel perspective by suggesting that the Warburg effect may not only be central to tumor cell proliferation but also to the proliferation of mesangial cells. These findings indicated that circRNA_0013747 was elevated in IgAN tissues and induced mesangial cell proliferation and the Warburg effect by regulating the miR-330-3p/PKM2 signaling pathway. Therefore, our study suggested that circRNA_0013747 could serve as a promising new biological marker and therapeutic target for IgAN.